HIPERDART
Development of High Performance Diagnostic Array Replication Technology
| Coordinatore | MOLECULAR STAMPING SRL
Organization address
address: Via Manzoni 16 contact info |
| Nazionalità Coordinatore | Italy [IT] |
| Totale costo | 3˙956˙572 € |
| EC contributo | 2˙999˙882 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2007-B |
| Funding Scheme | CP-TP |
| Anno di inizio | 2009 |
| Periodo (anno-mese-giorno) | 2009-01-01 - 2012-12-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
MOLECULAR STAMPING SRL
Organization address
address: Via Manzoni 16 contact info |
IT (TRENTO) | coordinator | 556˙859.00 |
| 2 |
INSTITUT CATALA D'ONCOLOGIA
Organization address
address: "AVDA. Gran Via KM 2,7 S/N" contact info |
ES ("HOSPITALET DEL LLOBREGAT, BARCELONA") | participant | 571˙397.00 |
| 3 |
THINXXS MICROTECHNOLOGY AG
Organization address
address: AMERIKASTRASSE 21 contact info |
DE (ZWEIBRUCKEN) | participant | 513˙166.00 |
| 4 |
CROSSLINKS BV
Organization address
address: WILLEMSKADE 18C contact info |
NL (ROTTERDAM) | participant | 470˙929.00 |
| 5 |
KUNGLIGA TEKNISKA HOEGSKOLAN
Organization address
address: Valhallavaegen 79 contact info |
SE (STOCKHOLM) | participant | 317˙661.00 |
| 6 |
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE
Organization address
address: BATIMENT CE 3316 STATION 1 contact info |
CH (LAUSANNE) | participant | 290˙786.00 |
| 7 |
FONDAZIONE BRUNO KESSLER
Organization address
address: VIA SANTA CROCE 77 contact info |
IT (TRENTO) | participant | 279˙084.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Development of High Performance Diagnostic Array Replication Technology (HiPerDART) As with any new technology, the use of DNA microarrays has presented a number of important obstacles, many of which have limited their ability to move beyond research applications. For example, the data obtained from a traditional microarray experiment can fluctuate dramatically due to small perturbations in assay conditions. This fact, when coupled to the often extensive workflows required to perform an assay, has caused many experts to conclude that microarrays are not well suited to clinical applications. Other factors as limited content flexibility and high production costs contribute to this negative image. It is the aim of the present HiPerDART project to develop a higher standard (clinical) microarray technology platform, by proposing a highly innovative probe printing technology, called Supramolecular NanoStamping (SuNS). Moreover, since at the same time in HiPerDART both assay workflow will be minimized and signal-to-noise ratios will be improved, our technology platform promises to dramatically improve the reliability (reproducibility and costs) of these (medical) tests. Furthermore, in an industry dominated by U.S. players, it is imperative to establish a strong European presence at this early stage in the development of the clinical market. By using a complex disease as colon cancer to prove the strength of the HiPerDART microarray technology platform, already in the limited lifetime of this project a first HiPerDART diagnostic microarray test will be validated.'